A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals

This is a Phase 1/2 observer-blind, multicenter, randomized, active-controlled, dose-selection study. The study will evaluate the safety characteristics of the VZV modRNA vaccine how well it is tolerated, and whether it can stimulate production of antibodies (immune responses) against VZV (shingles) in healthy individuals 50 through 69 years of age. 

The George Washington University is seeking volunteers for a shingles vaccine clinical trial who are:

Between the ages 50-69, healthy, and living in the DC metro area

Have never had shingles or received a shingles vaccine

Interested? Follow this link to sign up for the study: https://redcap.link/gwshingles

More information regarding the study can be found at clinicaltrials.gov.


Pfizer Inc.
Principal Investigator(s)
Dr. David Diemert
Contact Phone Number
Request Information
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.